< em > P. aeruginosa < /em > tRNA-fMet halves secreted in outer membrane vesicles suppress lung inflammation in Cystic Fibrosis
In conclusion, we have shown in mice and in vitro studies on CF-HBEC that tobramycin reduces inflammation by increasing 5' tRNA-fMet halves in OMVs that are delivered to CF-HBEC and reduce IL-8 and neutrophilic airway inflammation. This effect is predicted to improve lung function in pwCF receiving tobramycin for P. aeruginosa infection.PMID:38440830 | DOI:10.1152/ajplung.00018.2024 (Source: American Journal of Physiology. Lung Cellular and Molecular Physiology)
Source: American Journal of Physiology. Lung Cellular and Molecular Physiology - March 5, 2024 Category: Cytology Authors: Zhongyou Li Roxanna Barnaby Amanda B Nymon Carolyn Roche Katja Koeppen Alix Ashare Deborah A Hogan Scott A Gerber Douglas J Taatjes Thomas H Hampton Bruce A Stanton Source Type: research
< em > P. aeruginosa < /em > tRNA-fMet halves secreted in outer membrane vesicles suppress lung inflammation in Cystic Fibrosis
In conclusion, we have shown in mice and in vitro studies on CF-HBEC that tobramycin reduces inflammation by increasing 5' tRNA-fMet halves in OMVs that are delivered to CF-HBEC and reduce IL-8 and neutrophilic airway inflammation. This effect is predicted to improve lung function in pwCF receiving tobramycin for P. aeruginosa infection.PMID:38440830 | DOI:10.1152/ajplung.00018.2024 (Source: Am J Physiol Lung Ce...)
Source: Am J Physiol Lung Ce... - March 5, 2024 Category: Respiratory Medicine Authors: Zhongyou Li Roxanna Barnaby Amanda B Nymon Carolyn Roche Katja Koeppen Alix Ashare Deborah A Hogan Scott A Gerber Douglas J Taatjes Thomas H Hampton Bruce A Stanton Source Type: research
< em > P. aeruginosa < /em > tRNA-fMet halves secreted in outer membrane vesicles suppress lung inflammation in Cystic Fibrosis
In conclusion, we have shown in mice and in vitro studies on CF-HBEC that tobramycin reduces inflammation by increasing 5' tRNA-fMet halves in OMVs that are delivered to CF-HBEC and reduce IL-8 and neutrophilic airway inflammation. This effect is predicted to improve lung function in pwCF receiving tobramycin for P. aeruginosa infection.PMID:38440830 | DOI:10.1152/ajplung.00018.2024 (Source: American Journal of Physiology. Lung Cellular and Molecular Physiology)
Source: American Journal of Physiology. Lung Cellular and Molecular Physiology - March 5, 2024 Category: Cytology Authors: Zhongyou Li Roxanna Barnaby Amanda B Nymon Carolyn Roche Katja Koeppen Alix Ashare Deborah A Hogan Scott A Gerber Douglas J Taatjes Thomas H Hampton Bruce A Stanton Source Type: research
< em > P. aeruginosa < /em > tRNA-fMet halves secreted in outer membrane vesicles suppress lung inflammation in Cystic Fibrosis
In conclusion, we have shown in mice and in vitro studies on CF-HBEC that tobramycin reduces inflammation by increasing 5' tRNA-fMet halves in OMVs that are delivered to CF-HBEC and reduce IL-8 and neutrophilic airway inflammation. This effect is predicted to improve lung function in pwCF receiving tobramycin for P. aeruginosa infection.PMID:38440830 | DOI:10.1152/ajplung.00018.2024 (Source: Am J Physiol Lung Ce...)
Source: Am J Physiol Lung Ce... - March 5, 2024 Category: Respiratory Medicine Authors: Zhongyou Li Roxanna Barnaby Amanda B Nymon Carolyn Roche Katja Koeppen Alix Ashare Deborah A Hogan Scott A Gerber Douglas J Taatjes Thomas H Hampton Bruce A Stanton Source Type: research
< em > P. aeruginosa < /em > tRNA-fMet halves secreted in outer membrane vesicles suppress lung inflammation in Cystic Fibrosis
In conclusion, we have shown in mice and in vitro studies on CF-HBEC that tobramycin reduces inflammation by increasing 5' tRNA-fMet halves in OMVs that are delivered to CF-HBEC and reduce IL-8 and neutrophilic airway inflammation. This effect is predicted to improve lung function in pwCF receiving tobramycin for P. aeruginosa infection.PMID:38440830 | DOI:10.1152/ajplung.00018.2024 (Source: American Journal of Physiology. Lung Cellular and Molecular Physiology)
Source: American Journal of Physiology. Lung Cellular and Molecular Physiology - March 5, 2024 Category: Cytology Authors: Zhongyou Li Roxanna Barnaby Amanda B Nymon Carolyn Roche Katja Koeppen Alix Ashare Deborah A Hogan Scott A Gerber Douglas J Taatjes Thomas H Hampton Bruce A Stanton Source Type: research
< em > P. aeruginosa < /em > tRNA-fMet halves secreted in outer membrane vesicles suppress lung inflammation in Cystic Fibrosis
In conclusion, we have shown in mice and in vitro studies on CF-HBEC that tobramycin reduces inflammation by increasing 5' tRNA-fMet halves in OMVs that are delivered to CF-HBEC and reduce IL-8 and neutrophilic airway inflammation. This effect is predicted to improve lung function in pwCF receiving tobramycin for P. aeruginosa infection.PMID:38440830 | DOI:10.1152/ajplung.00018.2024 (Source: Am J Physiol Lung Ce...)
Source: Am J Physiol Lung Ce... - March 5, 2024 Category: Respiratory Medicine Authors: Zhongyou Li Roxanna Barnaby Amanda B Nymon Carolyn Roche Katja Koeppen Alix Ashare Deborah A Hogan Scott A Gerber Douglas J Taatjes Thomas H Hampton Bruce A Stanton Source Type: research
< em > P. aeruginosa < /em > tRNA-fMet halves secreted in outer membrane vesicles suppress lung inflammation in Cystic Fibrosis
In conclusion, we have shown in mice and in vitro studies on CF-HBEC that tobramycin reduces inflammation by increasing 5' tRNA-fMet halves in OMVs that are delivered to CF-HBEC and reduce IL-8 and neutrophilic airway inflammation. This effect is predicted to improve lung function in pwCF receiving tobramycin for P. aeruginosa infection.PMID:38440830 | DOI:10.1152/ajplung.00018.2024 (Source: American Journal of Physiology. Lung Cellular and Molecular Physiology)
Source: American Journal of Physiology. Lung Cellular and Molecular Physiology - March 5, 2024 Category: Cytology Authors: Zhongyou Li Roxanna Barnaby Amanda B Nymon Carolyn Roche Katja Koeppen Alix Ashare Deborah A Hogan Scott A Gerber Douglas J Taatjes Thomas H Hampton Bruce A Stanton Source Type: research
< em > P. aeruginosa < /em > tRNA-fMet halves secreted in outer membrane vesicles suppress lung inflammation in Cystic Fibrosis
In conclusion, we have shown in mice and in vitro studies on CF-HBEC that tobramycin reduces inflammation by increasing 5' tRNA-fMet halves in OMVs that are delivered to CF-HBEC and reduce IL-8 and neutrophilic airway inflammation. This effect is predicted to improve lung function in pwCF receiving tobramycin for P. aeruginosa infection.PMID:38440830 | DOI:10.1152/ajplung.00018.2024 (Source: Am J Physiol Lung Ce...)
Source: Am J Physiol Lung Ce... - March 5, 2024 Category: Respiratory Medicine Authors: Zhongyou Li Roxanna Barnaby Amanda B Nymon Carolyn Roche Katja Koeppen Alix Ashare Deborah A Hogan Scott A Gerber Douglas J Taatjes Thomas H Hampton Bruce A Stanton Source Type: research
< em > P. aeruginosa < /em > tRNA-fMet halves secreted in outer membrane vesicles suppress lung inflammation in Cystic Fibrosis
In conclusion, we have shown in mice and in vitro studies on CF-HBEC that tobramycin reduces inflammation by increasing 5' tRNA-fMet halves in OMVs that are delivered to CF-HBEC and reduce IL-8 and neutrophilic airway inflammation. This effect is predicted to improve lung function in pwCF receiving tobramycin for P. aeruginosa infection.PMID:38440830 | DOI:10.1152/ajplung.00018.2024 (Source: American Journal of Physiology. Lung Cellular and Molecular Physiology)
Source: American Journal of Physiology. Lung Cellular and Molecular Physiology - March 5, 2024 Category: Cytology Authors: Zhongyou Li Roxanna Barnaby Amanda B Nymon Carolyn Roche Katja Koeppen Alix Ashare Deborah A Hogan Scott A Gerber Douglas J Taatjes Thomas H Hampton Bruce A Stanton Source Type: research
< em > P. aeruginosa < /em > tRNA-fMet halves secreted in outer membrane vesicles suppress lung inflammation in Cystic Fibrosis
In conclusion, we have shown in mice and in vitro studies on CF-HBEC that tobramycin reduces inflammation by increasing 5' tRNA-fMet halves in OMVs that are delivered to CF-HBEC and reduce IL-8 and neutrophilic airway inflammation. This effect is predicted to improve lung function in pwCF receiving tobramycin for P. aeruginosa infection.PMID:38440830 | DOI:10.1152/ajplung.00018.2024 (Source: Am J Physiol Lung Ce...)
Source: Am J Physiol Lung Ce... - March 5, 2024 Category: Respiratory Medicine Authors: Zhongyou Li Roxanna Barnaby Amanda B Nymon Carolyn Roche Katja Koeppen Alix Ashare Deborah A Hogan Scott A Gerber Douglas J Taatjes Thomas H Hampton Bruce A Stanton Source Type: research
< em > P. aeruginosa < /em > tRNA-fMet halves secreted in outer membrane vesicles suppress lung inflammation in Cystic Fibrosis
In conclusion, we have shown in mice and in vitro studies on CF-HBEC that tobramycin reduces inflammation by increasing 5' tRNA-fMet halves in OMVs that are delivered to CF-HBEC and reduce IL-8 and neutrophilic airway inflammation. This effect is predicted to improve lung function in pwCF receiving tobramycin for P. aeruginosa infection.PMID:38440830 | DOI:10.1152/ajplung.00018.2024 (Source: American Journal of Physiology. Lung Cellular and Molecular Physiology)
Source: American Journal of Physiology. Lung Cellular and Molecular Physiology - March 5, 2024 Category: Cytology Authors: Zhongyou Li Roxanna Barnaby Amanda B Nymon Carolyn Roche Katja Koeppen Alix Ashare Deborah A Hogan Scott A Gerber Douglas J Taatjes Thomas H Hampton Bruce A Stanton Source Type: research
Remodeling of Paranasal Sinuses Mucosa Functions in Response to Biofilm-Induced Inflammation
J Inflamm Res. 2024 Feb 26;17:1295-1323. doi: 10.2147/JIR.S443420. eCollection 2024.ABSTRACTRhinosinusitis (RS) is an acute (ARS) or chronic (CRS) inflammatory disease of the nasal and paranasal sinus mucosa. CRS is a heterogeneous condition characterized by distinct inflammatory patterns (endotypes) and phenotypes associated with the presence (CRSwNP) or absence (CRSsNP) of nasal polyps. Mucosal barrier and mucociliary clearance dysfunction, inflammatory cell infiltration, mucus hypersecretion, and tissue remodeling are the hallmarks of CRS. However, the underlying factors, their priority, and the mechanisms of inflammato...
Source: Cell Research - March 4, 2024 Category: Cytology Authors: Szczepan Kaliniak Krzysztof Fiedoruk Jakub Spa łek Ewelina Piktel Bonita Durna ś Stanis ław Góźdź Robert Bucki S ławomir Okła Source Type: research
Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility
The treatment of cystic fibrosis (CF) changed dramatically with the advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies that address the underlying cause of the disease. With the approval of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA), CFTR modulators can now treat most people with CF (pwCF). Clinical benefits observed in trials and in real-world data demonstrate substantial improvements in lung function, pulmonary exacerbations, nutritional measures, and transplant and mortality outcomes in patients treated with ELX/TEZ/IVA [1,2]. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - March 4, 2024 Category: Respiratory Medicine Authors: Jaime L. Rubin, James L. Kreindler Tags: Letter to the Editor Source Type: research
Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation
CFTR modulators (CFTRm) have revolutionized the world of many people with cystic fibrosis (pwCF), but not for all. The most common mutation, the F508del mutation, leads to a processing and trafficking defect resulting in reduced functioning and quantity of the CFTR on the cell membrane. Subjects homozygous for the F508del mutation are defined as having minimal function of the CFTR protein, and tend to present with more severe phenotype. In the heterozygous states with a residual function mutation, subjects tend to have milder phenotype [1]. (Source: Journal of Cystic Fibrosis)
Source: Journal of Cystic Fibrosis - March 4, 2024 Category: Respiratory Medicine Authors: Bat El Bar Aluma, Joel Reiter, Ori Efrati, Yael Bezalel, Shlomit Keler, Moshe Ashkenazi, Adi Dagan, Yael Buchnik, Ido Sadras, Malena Cohen-Cymberknoh Tags: Original Article Source Type: research
Constitutional chromosomal anomalies in children, fetal alcohol syndrome, and maternal toxicant exposures: A longitudinal cohort study
Mutat Res Genet Toxicol Environ Mutagen. 2024 Feb-Mar;894:503737. doi: 10.1016/j.mrgentox.2024.503737. Epub 2024 Feb 9.ABSTRACTDNA alterations in gametes, which may occur either spontaneously or as a result of exposure to genotoxicants, can lead to constitutional chromosomal anomalies in the offspring. Alcohol is an established genotoxicant. The goal of this hypothesis-testing longitudinal cohort study was to evaluate the effect of significant/sustained maternal alcohol exposure on clinically diagnosed constitutional chromosomal anomalies among children diagnosed with fetal alcohol syndrome (FAS). De-identified eligibility...
Source: Cell Research - March 3, 2024 Category: Cytology Authors: David A Geier Mark R Geier Source Type: research
